Decreased prefrontal glutamatergic function is associated with a reduced astrocyte-related gene expression in treatment-resistant depression
Glutamatergic dysfunction is involved in the pathophysiology of treatment-resistant depression (TRD). However, few physiological studies have evaluated its pathophysiology in vivo in individuals with TRD. Transcranial magnetic stimulation-electroencephalography (TMS-EEG) techniques can assess intracortical facilitation (ICF), which reflects glutamatergic neurophysiological function in specific cortical regions. The objectives of this study were (1) to compare glutamatergic receptor-mediated function as indexed with ICF TMS-EEG in the dorsolateral prefrontal cortex (DLPFC) between participants with TRD and healthy controls (HCs) and (2) to explore the relationships between cell-specific gene expression levels and the group difference in glutamatergic neural propagation using virtual histology approach. Sixty participants with TRD and thirty HCs were examined with ICF TMS-EEG measure (80 single-pulse TMS and paired-pulse ICF) in the left DLPFC. Both sensor and source-level ICF measures were computed to compare them between the TRD and HC groups. Furthermore, we conducted spatial correlation analyses interregionally between ICF glutamatergic activity and cell-specific gene expression levels employing the Allen Human Brain Atlas dataset. DLPFC-ICF at the sensor level was not significantly different between the two groups, whereas DLPFC-ICF at the source level was reduced in the TRD group compared with the HC group (p = 0.026). Moreover, the reduced ICF signal propagation of TRD correlated with astrocyte-specific gene expression level (p < 0.0001). The glutamatergic neural activities indexed by ICF in the left DLPFC were decreased in participants with TRD. Additionally, a relative reduction in glutamatergic signal propagation originating from the DLPFC in TRD may be associated with astrocytic abnormality.
Authors
- Satoki Homma (ORCID: https://orcid.org/0000-0003-4392-1064)
- Keita Taniguchi (ORCID: https://orcid.org/0009-0002-0643-8452)
- Masaru Mimura (ORCID: https://orcid.org/0000-0002-3874-5273)
- Yoshihiro Noda (ORCID: https://orcid.org/0000-0002-2155-0357)
- Shinya Fujii (ORCID: https://orcid.org/0000-0001-5003-2367)
- Shinichiro Nakajima (ORCID: https://orcid.org/0000-0002-2601-2195)
- Masataka Wada (ORCID: https://orcid.org/0000-0002-3937-3619)
- Yu Mimura (ORCID: https://orcid.org/0000-0003-0538-6785)
- Yui Tobari
- Shiori Honda (ORCID: https://orcid.org/0000-0002-3756-0584)
- Mayuko Takano (ORCID: https://orcid.org/0000-0002-4756-1601)
- Ryo Ueda (ORCID: https://orcid.org/0000-0001-8302-155X)
Institutions
- Keio University (JP)
- Mita Hospital (JP)
- Teijin (Japan) (JP)
- Stanford University (US)
Publication Details
- Journal
- Translational Psychiatry
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1038/s41398-024-03186-2
- Citations
- 10
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.57
Funders
- Japan Society for the Promotion of Science